



**Silence Therapeutics plc  
(‘Silence Therapeutics’, ‘the Group’ or ‘the Company’)**

**Silence Therapeutics to Present at the Lazard Capital Markets Fourth Annual  
Healthcare Conference**

**London, 19 November 2007** – Silence Therapeutics plc (LSE:SLN), a leading European RNAi therapeutics company, announces that the company will be presenting at the Lazard Capital Markets Fourth Annual Healthcare Conference, 27 - 28 November, New York, NY, USA. The company’s Chief Executive Officer, Jeff Vick, is scheduled to present at 10:30am on 28 November. A webcast of the presentation will be available on <http://www.wsw.com/webcast/lz4/sln.ln/>.

- Ends -

Enquiries:

**Silence Therapeutics plc**  
+44(0)20 3102 5130  
Jeff Vick, Chief Executive Officer  
Melvyn Davies, Finance Director

**Investor Relations**  
**Citigate Dewe Rogerson**  
+44(0)20 7638 9571  
David Dible  
Yvonne Alexander

## **Notes to Editors**

**Silence Therapeutics plc** ([www.silence-therapeutics.com](http://www.silence-therapeutics.com))

**Silence Therapeutics plc (LSE:SLN)** is a leading RNAi company. RNA interference (RNAi) can selectively ‘silence’ genes linked to the onset of disease.

Silence Therapeutics has developed novel, proprietary short interfering RNA (‘siRNA’) molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules as they show increased stability against nuclease degradation. In addition, the Company has developed a proprietary systemic delivery system, AtuPLEX. This enables the delivery of siRNA molecules to targeted diseased tissues and cells, whilst increasing their bioavailability and intracellular uptake.

In July 2007, Silence Therapeutics formed a research and development collaboration with Astra Zeneca to develop AtuRNAi against five targets including those in respiratory indications. The Group’s AtuRNAi technology also has been sublicensed to Pfizer through Quark’s license to Pfizer of the compound RTP-801i-14 for the treatment of Age-related Macular Degeneration (AMD) and a number of other indications. This compound

entered the clinic in early 2007. Silence Therapeutics also has licensed to Quark rights to the AtuRNAi structure for its proprietary compound AKli-5. This compound has been granted an IND for acute kidney injury and is expected to enter the clinic in 2007. In addition, Silence Therapeutics expects to begin the clinical development of its proprietary AtuRNAi therapeutic molecules for systemic cancer indications in 2008.

Silence Therapeutics is based in London, UK, and Berlin, Germany, and is listed on AIM.

#### About RNAi

RNA interference (RNAi), a Nobel Prize winning technology, is one of the most exciting areas of drug discovery today. It represents a completely new approach to selectively 'silence' or inactivate disease relevant genes and as such it has the potential to create a new class of therapeutic products. RNAi could therefore offer a therapeutic approach to a broad range of diseases (cancer, infectious diseases, inherited diseases), many of which have been regarded as incurable and are not addressed by current therapeutics, therefore providing a large market opportunity.